DOCSLIB.ORG

Jefferies 2014 Global Healthcare Conference in London

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jefferies 2014 Global Healthcare Conference in London Jefferies 2014 Global Healthcare Conference in London You are invited to attend the Jefferies Global Healthcare Conference on 19-20 November, 2014, at the Waldorf Hilton in London. Now in its fifth year, ours is the largest healthcare-dedicated conference in Europe. Last year, we had 230 participating healthcare companies with a combined market capitalisation of over INVITATION $1 trillion and close to 2,250 1x1/small-group meetings. The 2014 conference is set to follow 19-20 NOVEMBER 2014 in the same footsteps, featuring leading public and private companies from areas of The Waldorf Hilton pharmaceuticals, biotechnology, generics, consumer health, animal health, medical London, UK technology and healthcare services from the United States, Western and Emerging Europe, Middle East & Africa, Latin America, Russia, India, Israel, China, and Japan. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative © 2014 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, NOVEMBER 19, 2014 Jefferies 2014 Global Healthcare Conference in London TRACK 1 TRACK 2 TRACK 3 TRACK 4 TRACK 5 ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM ALDWYCH 7:30 AM Breakfast and Registration 8:00 AM EMIS Group PLC( AIM:EMIS) Auris Medical Holding AG Sartorius AG (DB:SRT) Medivation, Inc.(NasdaqGS:MDVN) Ethypharm SA (Private) Healthcare Technology (NasdaqGM:EARS) Medical Products & Devices Biotechnology Pharmaceuticals Chris Spencer, CEO Pharmaceuticals Joerg Pfirrmann, CFO David Hung, M.D., President and CEO Hugues Lecat, CEO and Chairman of the Dr. Thomas Meyer, CEO Management Board 8:40 AM Circassia Limited (LSE:CIR) Amgen Inc. (NasdaqGS:AMGN) Spectrum Pharmaceuticals, Inc. PDL BioPharma, Inc. (NasdaqGS:PDLI) Ablynx NV (ENXTBR:ABLX) Biotechnology Biotechnology (NasdaqGS:SPPI) Life Sciences Biotechnology Steven Harris, CEO Arvind Sood, Vice President of IR Biotechnology John McLaughlin, President & CEO Edwin Moses, CEO Rajesh Shrotriya, Chairman & Chief Executive Officer 9:20 AM BTG Plc (LSE:BTG) Acorda Therapeutics, Inc. Gerresheimer AG (DB:GXI) CTI BioPharma Corp. (NasdaqCM:CTIC) ReWalk Robotics Ltd. (NasdaqGM:RWLK) Biotechnology (NasdaqGS:ACOR) Medical Products & Devices Biotechnology Medical Products & Devices Louise Makin, CEO Biotechnology Mrs. Anke Linnartz, Director Corporate Jim Bianco, President and CEO Larry Jasinski, CEO Andrew Blight, Chief Scientific Officer Investor Relations & Creditor Relations 10:00 AM Hikma Pharmaceuticals plc (LSE:HIK) Swedish Orphan Biovitrum AB Henry Schein, Inc. (NasdaqGS:HSIC) Actelion Ltd. (SWX:ATLN) Flamel Technologies SA (NasdaqGM:FLML) Pharmaceuticals (OM:SOBI) Healthcare Services Biotechnology Khalid Nabilsi, CFO Pharmaceuticals Ferdinand Jahnel, VP & Treasurer Andrew Weiss, Head Investor Relations & Pharmaceuticals Corporate Communications Michael Anderson, CEO Geoff McDonough, CEO 10:40 AM Pacira Pharmaceuticals Inc. Reckitt Benckiser Pharmaceuticals GN Store Nord A/S (CPSE:GN) Cosmo Pharmaceuticals SpA uniQure N.V. (NasdaqGS:QURE) (NasdaqGS:PCRX) (Indivior)(LSE:RB.) Medical Products & Devices (SWX:COPN) Biotechnology Pharmaceuticals Michael Bjergby, Vice President - Biotechnology Jörn Aldag, CEO Pharmaceuticals Shaun Thaxter, CEO Alessandro Della Cha, CEO Jim Scibetta, Senior Vice President & CFO IR & Treasury 11:20 AM Spire Healthcare Group Plc (LSE:SPI) Novartis AG (SWX:NOVN) PerkinElmer, Inc. (NYSE:PKI) Tesaro, Inc (NasdaqGS:TSRO) Immune Design Corp. (NasdaqGM:IMDZ) Healthcare Services Pharmaceuticals Life Sciences Tools and Services Biotechnology Biotechnology Antony Mannion, Investor Relations Rainer Boehm, Chief Commercial Officer Robert Friel, Chairman and CEO Lonnie Moulder, CEO Carlos Paya, CEO Director 12:00 PM Break – Working Lunch Presenting companies and speakers are subject to change. AGENDA WEDNESDAY, NOVEMBER 19, 2014 Jefferies 2014 Global Healthcare Conference in London TRACK 1 TRACK 2 TRACK 3 TRACK 4 TRACK 5 ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM ALDWYCH 12:20 PM Clinigen Group Plc (AIM:CLIN) Laboratorios Farmaceuticos ROVI, S.A. Panel - Trials and tribulations of emerging Pixium Vision (PIX FP) Cempra, Inc. (NasdaqGM:CEMP) Healthcare Services (CATS:ROVI) markets in the Pharma Sector Medical Technology Biotechnology Peter George, CEO Pharmaceuticals Bernard Gilly, Executive Chairman Prabhavathi Fernandes, Ph.D., Founder, Javier López-Belmonte, CFO President and CEO 1:00 PM Tissue Regenix Group Plc (AIM:TRX) Cubist Pharmaceuticals Inc. Orpea S.A. (ENXTPA:ORP) IDT Biologika GmbH (Private) Bavarian Nordic A/S (CPSE:BAVA) Medical Technology (NasdaqGS:CBST) Healthcare Services Animal Health Biotechnology Biotechnology Antony Odell, CEO Steve Grobet, Investor Relations Officer Andreas Kastenbauer, COO & Dr. Paul Chaplin, President & CEO Steve Gilman, EVP & CSO Michael Hemprich, Head of Business Development 1:40 PM Novo Nordisk A/S (CPSE:NOVO B) Novozymes A/S (CPSE:NZYM B) MAXIMUS, Inc. (NYSE:MMS) Virbac SA (ENXTPA:VIRP) Progenics Pharmaceuticals, Inc. Pharmaceuticals Pharmaceuticals Healthcare Services Animal Health (NasdaqGS:PGNX) Biotechnology Peter Kurtzhals, SVP Diabetes Research Dave Mead, Business Development Richard Montoni, CEO Eric Maree, CEO Unit Director Jim Garrison, Head of Business Development and Commercial Strategy 2:20 PM Al Noor Hospitals Group Plc (LSE:ANH) Valeant Pharmaceuticals International Recipharm AB (OM:RECI B) Aratana Therapeutics, Inc. Galapagos NV ( ENXTBR:000381835) Healthcare Services (TSX:VRX) Pharmaceuticals (NasdaqGM:PETX) Biotechnology Sami Alom, Chief Strategy Officer & Pharmaceuticals Björn Westberg, CFO Animal Health Onno Van de Stolpe, CEO Director, Investor Relations Laurie Little, SVP, Investor Relations Steve St. Peter, President and CEO 3:00 PM Medical Properties Trust (NYSE:MPW) Akorn, Inc. (NasdaqGS:AKRX) ALK-Abello (CPSE:ALK B) Putney, Inc. (Private) MediWound Ltd. (NasdaqGM:MDWD) Services Pharmaceuticals Life Sciences Animal Health Pharmaceuticals Steve Hamner, CFO Tim Dick, CFO Flemming Pedersen, CFO and EVP Jean Hoffman, Founder, Chairman and Gal Cohen, CEO Chief Executive Officer 3:40 PM Forward Pharma A/S (NasdaqGS:FWP) Ipsen S.A (ENXTPA:IPN) Neurocrine Biosciences, Inc. Parnell Pharmaceuticals Holdings Ltd. Verastem, Inc. (NasdaqGM:VSTM) Biotechnology Pharmaceuticals (NasdaqGS:NBIX) (NasdaqGM:PARN) Biotechnology Joel Sendek, CFO Marc De Garidel, CEO Biotechnology Animal Health Robert Forrester, CEO Kevin Gorman, President & CEO Robert Joseph, CEO 4:20 PM GW Pharmaceuticals plc (AIM:GWP) OpKo Health, Inc (NYSE:OPK) SciClone Pharmaceuticals, Inc. Sequent Scientific Ltd. (BSE:512529) Prosensa Holding N.V. (NasdaqGS:RNA) Pharmaceuticals Pharmaceuticals (NasdaqGS:SCLN) Animal Health Biotechnology Justin Gover, CEO Steven Rubin, Executive Vice President - Biotechnology Manish Gupta, CEO Hans Schikan, CEO Admistration Friedhelm Blobel, CEO 5:00 PM Norgine (Private) Helsinn Healthcare SA (Private) Transgene SA (ENXTPA:TNG) Pharmaceuticals Pharmaceuticals Biotechnology Peter Stein, CEO Riccardo Braglia, CEO Elisabetta Castelli, Director, Investor Relations Presenting companies and speakers are subject to change. AGENDA THURSDAY, NOVEMBER 20, 2014 Jefferies 2014 Global Healthcare Conference in London TRACK 1 TRACK 2 TRACK 3 TRACK 4 TRACK 5 ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM ALDWYCH 7:30 AM Breakfast and Registration 8:00 AM Stratec Biomedical AG (DB:SBS) Vectura Group Plc (LSE:VEC) NPS Pharmaceuticals Inc. Kamada Ltd. (TASE:KMDA) Syneron Medical Ltd. (NasdaqGS:ELOS) Life Sciences Pharmaceuticals (NasdaqGS:NPSP) Biotechnology Medical Products & Devices Marcus Wolfinger, CEO Dr Chris Blackwell, CEO Biotechnology Gil Efron, CFO Hugo Goldman, CFO Francois Nader, MD, President & CEO 8:40 AM Alere Inc. (NYSE:ALR) Avalanche Biotechnologies, Inc. Haemonetics Corp (NYSE:HAE) Innate Pharma S.A. (ENXTPA:IPH) AMCo (Private) Medical Technology (NasdaqGM:AAVL) Medical Products & Devices Biotechnology Pharmaceuticals Namal Nawana, Interim CEO Biotechnology Christopher Lindop, CFO & EVP, Business Herve Brailly, CEO John Beighton, CEO Linda Bain, CFO Development 9:20 AM AMAG Pharmaceuticals, Inc. AbbVie Inc. (NYSE:ABBV) Ascendis Health Limited (JSE:ASC) ACADIA Pharmaceuticals Inc. RIEMSER Pharma GmbH (Private) (NasdaqGS:AMAG) Pharmaceuticals Pharmaceuticals (NasdaqGS:ACAD) Pharmaceuticals Pharmaceuticals Bill Chase, Executive Vice President - Dr. Karsten Wellner, CEO Biotechnology Kai Deusch, CEO Bill Heiden, CEO Chief Operating Officer Uli Hacksell, CEO 10:00 AM PT Siloam International Hospitals Tbk Roche Holding Ltd. (SWX:ROG) Nektar Therapeutics (NasdaqGS:NKTR) Dicerna Pharmaceuticals, Inc. Alvogen Group (Private) (JKSE:SILO) Pharmaceuticals Biotechnology (NasdaqGS:DRNA) Pharmaceuticals Healthcare Facilities Bill Anderson, Head of Global Product Dr. Ivan Gergel, Chief Medical Officer Biotechnology Robert Wessman, CEO Dr. Gershu Paul, CEO Strategy and Chief Marketing Officer James Dentzer, CFO Kevin Bain, CFO 10:40 AM Abiomed Inc. H. Lundbeck A/S (CPSE:LUN) Kite Pharma, Inc. (NasdaqGS:KITE) Compugen Ltd. (NasdaqCM:CGEN) Doc Generici S.R.L. (Private) (NasdaqGS:ABMD)
Load more

Recommended publications
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • The Confusions in Nordic ESG Ratings
    Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters.
    [Show full text]
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Ifu Project Portfolio 2018 2 | Ifu Project Portfolio 2018
    IFU PROJECT PORTFOLIO 2018 2 | IFU PROJECT PORTFOLIO 2018 PROJECT Portfolio INDEPENDENT AUDitors’ report ON IFU PROJECT Portfolio 2018 Up to the end of 2018, IFU and IFU managed funds had co-financed To the Executive Board of IFU standards, applicable requirements in Danish law and other regulations. a total of 1,286 projects in 101 countries. Of these, 203 are ongoing As agreed, we have examined the IFU Project Portfolio 2018. The IFU We complied with independence requirements and other ethical stand- investments, while IFU has exited 1,083 projects. The distribution of Project Portfolio 2018 has been listed and presented in accordance with ards under FSR - Danish Auditors’ Code of Ethics for Professional all projects by region is illustrated in the figure below. the methodology and definitions described in “Note to IFU’s project Accountants, which rely on general principles regarding integrity, ob- portfolio – definitions (only in English)”. jectivity, professional competence and due care, confidentiality and professional conduct. TotAL NUMBER OF projects DistriButeD BY REGION We are to conclude on IFU Project Portfolio 2018 to ascertain whether the data and information are correctly reflected in accordance with the As part of our examinations, we performed the below procedures: methodology and definitions reflected in “Note to IFU project portfolio • A sample check of whether IFU’s recordings of the individual share Africa 278 –definitions”. The IFU Project Portfolio 2018 means IFU’s involvement capital investments/project loans, total disbursed and expected total Asia 422 in active and finalised projects, as presented by the Executive Board and investment are reconciled in accordance with the contractual frame- Europe 445 in accordance with the principles and definitions reflected in “Note to work and information provided.
    [Show full text]
  • Sartorius Group 2016 Annual Report Order Intake and Sales Revenue Underlying EBITDA and Margin1) ¤ in Millions
    Sartorius Group 2016 Annual Report Order Intake and Sales Revenue Underlying EBITDA and Margin1) ¤ in millions 866.8 912.3 819.6 929.2 1,172.7 1,334.7 161.1 172.6 162.3 186.8 263.2 325.4 845.7 887.3 791.6 891.2 1,114.8 1,300.3 19.0 19.5 20.5 21.0 23.6 25.0 1,500 400 30 1,250 300 27 1,000 200 24 750 100 21 500 0 18 2012 2013 2013 2014 2015 2016 2012 2013 2013 2014 2015 2016 Continued operations Continued operations Q Order intake Q Underlying EBITDA in millions of ¤ QSales revenue Underlying EBITDA margin in % Key Figures All figures are given in millions of ¤ according 2016 2015 2014 2013 2013 2012 to the IFRS, unless otherwise specified restated Order intake, sales revenue and earnings Order intake 1,334.7 1,172.7 929.2 819.6 912.3 866.8 Sales revenue 1,300.3 1,114.8 891.2 791.6 887.3 845.7 Underlying EBITDA1) 325.4 263.2 186.8 162.3 172.6 161.1 Underlying EBITDA1) as a % of sales revenue 25.0 23.6 21.0 20.5 19.5 19.0 Relevant net profit for continuing operations2) 132.6 107.4 66.1 59.2 – – Relevant net profit2) 132.6 107.4 73.7 64.8 64.8 63.0 Research and development costs 59.4 52.5 43.63) 47.7 53.8 49.0 Financial data per share4) Earnings per share continued operations2) per ordinary share (in ¤) 1.93 1.57 0.96 0.86 – – per preference share (in ¤) 1.94 1.58 0.97 0.87 – – Earnings per share2) per ordinary share (in ¤) 1.93 1.59 1.07 0.95 0.95 0.92 per preference share (in ¤) 1.94 1.60 1.08 0.96 0.96 0.93 Dividends per ordinary share (in ¤) 0.455) 0.37 0.26 0.25 0.25 0.23 per preference share (in ¤) 0.465) 0.38 0.27 0.26 0.26 0.24 Balance
    [Show full text]
  • TO the SHAREHOLDERS of H. LUNDBECK A/S NOTICE of ANNUAL GENERAL MEETING Notice Is Hereby Given of the Annual General Meeting Of
    TO THE SHAREHOLDERS OF H. LUNDBECK A/S NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the Annual General Meeting of H. Lundbeck A/S to be held on: Thursday, 21 March 2013 at 10:00 AM The Annual General Meeting will be held at the Company’s address: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as fol- lows: 1. Report of the Board of Directors on the Company's activities during the past year. 2. Presentation and adoption of the annual report. 3. Approval of remuneration for the Board of Directors for the current financial year. 4. Resolution on the appropriation of profit or loss as recorded in the adopted annual report. 5. Election of members to the Board of Directors. 6. Election of one or two state-authorised public accountants. 7. Any proposal by shareholders or the Board of Directors. 8. Any other business. Complete proposals Re agenda item 1: The Board of Directors recommends that the report should be adopted. Re agenda item 2: It is proposed that the annual report should be adopted. Re agenda item 3: It is proposed that the remuneration for the Board of Directors for the current financial year should be the same as in 2012: - Ordinary members will receive a basic remuneration of DKK 300,000 - The chairman will receive three times the basic remuneration - The deputy chairman will receive two times the basic remuneration - Ordinary members of the Audit Committee, the Remuneration Committee and the Scien- tific Committee will receive DKK 200,000 in addition to the basic remuneration - The Committee chairmen will receive DKK 300,000 in addition to the basic remuneration Re agenda item 4: It is proposed that a dividend of 35% of the net profit for the year, corresponding to DKK 2.00 per share, or a total dividend of DKK 392 million, should be distributed for the financial year 2012.
    [Show full text]
  • Financial Results & Business Update Q1 2021
    Financial results & business update Q1 2021 11 MAY, 2021 COMPANY DISCLAIMER This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses. The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation.
    [Show full text]
  • QIAGEN N.V., Venlo, Niederlande
    QIAGEN N.V., Venlo, Niederlande Einladung zur ordentlichen Hauptversammlung Wir laden hiermit unsere Aktionäre zur ordentlichen Hauptversammlung der QIAGEN N.V. am Dienstag, den 30. Juni 2020 um 15.00 Uhr am Sitz der Gesellschaft, Hulsterweg 82, 5912 PL Venlo, Niederlande, ein. Aufgrund der Corona Pandemie und um unsere Aktionäre und alle anderen Teilnehmer der ordentlichen Hauptversammlung bestmöglich zu schützen, findet die Hauptversammlung ausschließlich in virtueller Form statt und wird in englischer Sprache abgehalten. Aktionären wird folglich kein physischer Zutritt zur Hauptversammlung gewährt. Die Versammlung wird live per audio webcast auf der Internetseite der Gesellschaft unter www.qiagen.com übertragen. Hierfür ist eine vorherige Anmeldung nicht notwendig. Zusätzlich zu den jährlich wiederkehrenden Tagesordnungspunkten wird die ordentliche Hauptversammlung in diesem Jahr auch eine Reihe von Tagesordnungspunkten umfassen, die sich auf das empfohlene Angebot der Quebec B.V, einer hundertprozentigen Tochtergesellschaft von Thermo Fisher Scientific Inc., für den Erwerb aller Stammaktien der Gesellschaft, einschließlich aller zum Zeitpunkt der Abwicklung des Angebots bestehenden Nebenrechte, insbesondere der Gewinnanteilsberechtigung, gegen Zahlung einer unverzinslichen Bargegenleistung in Höhe von EUR 39,00 je Stammaktie. Die Fassung des Back-End-Beschlusses (Tagesordnungspunkt 18) ist eine der Angebotsbedingungen. Heute wurden die Angebotsunterlage und die gemeinsame begründete Stellungnahme von QIAGEN und dem Vorstand und dem Aufsichtsrat zum Übernahmeangebot veröffentlicht. Wir empfehlen Ihnen eindringlich, diese Dokumente sorgfältig durchzulesen, da sie wichtige Informationen über das Angebot enthalten. Die Tagesordnung der ordentlichen Hauptversammlung der Gesellschaft mit den Vorschlägen von Vorstand und Aufsichtsrat lautet wie folgt: Jährliche wiederkehrende Tagesordnungspunkte 1. Eröffnung 2. Bericht des Vorstands über das am 31. Dezember 2019 abgelaufene Geschäftsjahr 3.
    [Show full text]
  • Eurex Circular 043/14
    eurex circular 043/14 Date: 6 March 2014 Recipients: All Trading Participants of Eurex Deutschland and Eurex Zürich and Vendors Authorized by: Thomas Book Action required A. Single Stock Futures: Introduction of SSFs on Belgian, French, German, Italian, Spanish and Swiss underlyings; B. Equity options: Introduction of equity options on CompuGroup Medical AG, Flughafen Wien AG Inhaber-Aktien o.N. and Nemetschek AG Inhaber-Aktien o.N. Contact: Derivatives Trading Operations, T +49-69-211-1 12 10, Michael Durica, T +49-69-211-1 59 23 Content may be most important for: Attachments: Ü All departments 1. Updated Annexes A and B of the Contract Specifications for Futures Contracts and Options Contracts at Eurex Deutschland and Eurex Zürich 2. Market Maker Obligations (excerpt) Summary: The Management Board of Eurex Deutschland and the Executive Board of Eurex Zürich AG took the following decisions with effect from 10 March 2014: 1. Introduction of Single Stock Futures on Beneteau S.A. Actions Port. EO -,10, Société Foncière Lyonnaise SA Actions Port. EO 2, Carl Zeiss Meditec AG, Dt. Annington Immobilien SE Namens-Aktien o.N., CompuGroup Medical AG, CANCOM SE, Almirall S.A. Acciones Port. EO -,12, GameLoft SE Actions Port. EO 0,05, Helvetia Holding AG, KBC Ancora Actions au Port. o.N, LEG Immobilien AG, LPKF Laser & Electronics AG, C.M.B. (Cie Maritime Belge) SA Actions Nouvelles au Port.o.N., Nemetschek AG Inhaber-Aktien o.N., Norma Group SE, Telefonica Deutschland Holding, Swiss Prime Site AG, Sartorius AG, Temenos Group AG and Yoox S.p.A. Azioni nom.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Lundbeck Continues to Deliver Solid Growth for Strategic Brands and the Financial Guidance Range Has Been Updated
    Corporate Release Valby, Denmark, August 18, 2021 Financial report for the period January 1 to June 30, 2021 Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated HIGHLIGHTS Revenue reached DKK 8,233 million in the first half of 2021, a decline of 4% in local currencies because of generic erosion on Northera®. EBIT grew 58% compared to the same period in 2020 and reached DKK 1,478 million. EBIT margin reached 18.0%. EPS grew by 63% for the period, reaching DKK 5.03. In aggregate, strategic brands grew 13% in local currencies reaching DKK 4,408 million in the first half of the year or 54% of total revenue. In the second quarter of 2021, all strategic brands have resumed double-digit growth in local currencies. Based on trends in Trintellix and Rexulti, there is a gradual uptick in new patient starts supporting growth momentum. The newest product in the portfolio, Vyepti®, continues its strong momentum since launch in April 2020 and reached DKK 101 million in the second quarter of 2021 compared to DKK 14 million for the same period last year. Regulatory review is ongoing in 14 markets. Strategic brand performance: ➢ Revenue of Abilify Maintena®: DKK 1,197 million (up 5% in local currencies, +2% reported) ➢ Revenue of Brintellix®/Trintellix®: DKK 1,656 million (up 12% in local currencies, +5% reported) ➢ Revenue of Rexulti®/Rxulti®: DKK 1,378 million (up 9% in local currencies, -1% reported) ➢ Revenue of Vyepti®: DKK 177 million (up 1,245% in local currencies, +1,164% reported) Market performance: ➢ Revenue in North America: DKK 4,052 million (down 10% in local currencies, -17% reported) ➢ Revenue in International Markets: DKK 2,197 million (up 6% in local currencies, -1% reported) ➢ Revenue in Europe: DKK 1,729 million (up 3% in local currencies, +2% reported) In connection with the financial report, Lundbeck’s President and CEO Deborah Dunsire said: “I am proud of our performance and our solid financial results as the strategic brand growth accelerates post pandemic.
    [Show full text]